Ireland
--:--IST
Recruiting Not applicable

AVS Pulse Intravascular Lithotripsy™ (Pulse IVL™) to Open Vessels With Calcific Walls and Enhance Vascular Compliance and Remodeling for Coronary Artery Disease

NCT07510438 · tracked via the Priya Life Science Australia tracker
Sponsor
Amplitude Vascular Systems, Inc
Phase
Not applicable
Started
2026-05-08
Last updated
2026-08-17

Condition(s) studied

Coronary Arterial Disease (CAD)

Investigational drug(s) / intervention(s)

Pulse Intravascular Lithotripsy (Pulse IVL)

Pulse Intravascular Lithotripsy (Pulse IVL): The Pulse Intravascular Lithotripsy (Pulse IVL) System is used for the treatment of severely calcified stenotic de novo coronary arteries prior to stenting in patients with coronary artery disease.

Study summary

A prospective, open-label, multi-site, FIH with up to fifteen (n=15) patients to assess the safety and preliminary effectiveness of the AVS Pulse Intravascular Lithotripsy™ System (Pulse IVL™ System) when used for the treatment of coronary artery disease.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: * ≥ 18 years of age * Subjects with native coronary artery disease * Left ventricular ejection fraction (LVEF) ≥ 35% within 6 months * The target lesion must be a single de novo coronary lesion * The target lesion stenosis of left anterior descending artery (LAD), right coronary artery (RCA), left circumflex artery (LCX), or ramus intermedius (RI), or of their branches with Stenosis of ≥70% and \<100% or Stenosis ≥50% and \<70% with evidence of ischemia * Lesion length must not exceed 44 mm Key Exclusion Criteria: * Subject experienced an acute Myocardial Infarction (MI), either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) within 30 days prior to index procedure. * Subject has New York Heart Association (NYHA) class III or IV heart failure. * Subject has renal failure with serum creatinine \>2.5 mg/dL, or chronic dialysis. * Subject has a previous stent in the target vessel implanted within last six months. * Unprotected LMCA diameter stenosis \>30%. * Target lesion has a myocardial bridge. * Target vessel is excessively tortuous, defined as the presence of 2 or more bends \>90 degrees or 3 or more bends \>75 degrees. * Evidence of aneurysm in target vessel within 10 mm of the target lesion. * Target lesion in ostial location (LAD, RCA, LCX, or RI, within 5 mm of ostium) or in an unprotected LMCA. * Target lesion is a bifurcation with ostial diameter stenosis ≥30%. * Any previous stent within 10 mm of the target lesion.

Primary outcome measure(s)

  • Achieve residual stenosis (<50%) in conjunction with stenting in the absence of major device related adverse events — Completion of study procedure
  • Target lesion failure (TLF) — Within 30 days of study procedure

Trial sites (3)

FacilityCityRegionStatus
St. Vincent's Hospital Sydney New South Wales Recruiting
Monash Health, Victorian Heart Hospital Melbourne Victoria Recruiting
Auckland City Hospital Auckland New Zealand Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07510438 on ClinicalTrials.gov ↗ ← All trials in Australia